



American Journal of Epidemiology & Public Health

Review Article

Chronic Episodes of Migraine: An Insight -

Nida Tabassum Khan*

Department of Biotechnology, Faculty of Life Sciences & Informatics, Balochistan University of Information Technology, Engineering and Management Sciences, Takatu Campus, Airport Road, Quetta, Balochistan, Pakistan

***Address for Correspondence:** Nida Tabassum Khan, Department of Biotechnology, Faculty of Life Sciences & Informatics, Balochistan University of Information Technology, Engineering and Management Sciences, Takatu Campus, Airport Road, Quetta, Balochistan, Pakistan, Tel: +92-336-816-4903; E-mail: nidatabassumkhan@yahoo.com

Submitted: 18 January 2022; Approved: 24 January 2022; Published: 25 January 2022

Cite this article: Khan NT. Chronic Episodes of Migraine: An Insight. American J Epidemiol Public Health. 2022 January 25;6(1): 007-010. doi: 10.37871/ajeph.id51

Copyright: © 2022 Khan NT. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



ABSTRACT

Cerebral pains are routinely depicted as beating or pounding, yet they furthermore can be dull or strain or sharp. They routinely occur on piece of the head or in a specific region yet may incorporate the whole head, and they on occasion change starting with one side then onto the next. A spread can be a visual or material incapacity that can go previously or go with a cerebral pain. Visual airs are more typical and are consistently portrayed as shimmering lights, or as bends, shapes, tones or models. On occasion visual secondary effects can incorporate dull spots or total or midway loss of vision. A couple of examinations have shown a possible association between cerebral pains with environment and coronary ailment.

Keywords: Dihydroergotamine; Antimigraine; Neurogenic; Bioavailability; Cranial vasoconstriction

INTRODUCTION

Previous literature focuses on the consistency of migraine in individuals using survey-based method, which addresses questions with respect to cerebral pain and other effects from cerebral pain further followed by clinical examination [1,2]. Epidemiological surveys indicated that the normality of migraine incidence was approximately 23% to 29% in women and 15% to 20% in men [3,4]. The consistency of migraine declined with age in a wide range of individuals [5]. These examinations show that migraine is extensively more overwhelming than the as frequently as conceivable referred to figure of around 10% of the general population which doesn't seem, by all accounts, to be established on a particular review [6,7].

Gender based incidence of cerebral pain examined by neurological examination revealed that cerebral pain was reported 12% in males and 24% in females [8]. Migraine treatment has progressed however the question whether cerebral pain is basically a vascular or a neurological disorder still debatable [9]. Despite this discussion, the levels of serotonin (5-hydroxytryptamine; 5-HT), a vasoconstrictor and a central neurotransmitter, seem to decrease during cerebral pain (with related carotid vasodilatation) [10]. Without a doubt, 5-HT similarly as ergotamine, dihydroergotamine and other antimigraine experts continually produce vasoconstriction in the external carotid dispersal [11]. The most recent decade has seen the presence of sumatriptan and second period triptans (for instance zolmitriptan, rizatriptan, naratriptan), which has a spot with one more class of meds, by and by known as 5-HT_{1B/1D/1F} receptor agonists [12]. Appeared differently in relation to sumatriptan, the second-age triptans have a higher oral bioavailability and longer plasma half-life [13]. As per the vascular and neurogenic speculations of migraine, all triptans produce specific carotid vasoconstriction (through 5-HT_{1B} receptors) and presynaptic block of the trigeminovascular searing responses entrapped in cerebral pain (through 5-HT_{1D/5-HT_{1F}} receptors) [14,15]. Also, specific agonists at 5-HT_{1D} (PNU-142633) and 5-HT_{1F} (LY344864) receptors impede the trigeminovascular system without making vasoconstriction [16]. Regardless, PNU-142633 wound up being lacking in the extraordinary treatment of migraine, while LY344864 showed a couple of sufficiency when used in measurements which team up with 5-HT_{1B} receptors [17]. Finally, though the triptans are reasonable antimigraine experts making explicit cranial vasoconstriction, attempts are being settled on to make other strong antimigraine decisions acting through the quick bar of vasodilator instruments (for instance miscreants at CGRP receptors, foes at 5-HT₇ receptors, inhibitors of nitric oxide biosynthesis, etc) [18,19]. To a great extent the cerebral agony may be gone before by a focal neurological characteristic ("air") followed by headache (old style migraine); this air involves explicit motor (inadequacy or loss of movement) or possibly focal neurological (shining scotoma) manifestations [20,21].

Gaining precise and strong information on the inescapability of cerebral pain is essential for understanding the weight it puts on society [22]. But the investigation on transmission of cerebral pain depicted that only 24% of individuals have the direction and age-unequivocal regularity of migraine [23]. The inescapability of cerebral pain is around 6% among men and 15 to 17% among women [24]. Inescapability changes by age, extending to about age 40 years and declining from that point on in a wide range of individuals [25]. The direction extent also appears to contrast by age, growing from menarche to about age 42 years and declining starting there [26]. PubMed, Embase and Google Scholar informational indexes were used to recognize focuses on dealing with the ordinariness of cerebral pain among undergraduates yet different methodologies lead to extensive heterogeneity in the results [27]. It is shown that direction and scientific guidelines in a general sense sway the cerebral pain transcendence and may somewhat explain the heterogeneity between different studies [28].

A cross-sectional study conducted in King Abdul Aziz University, Jeddah, using ID Migraine test and, Numeric Pain Rating Scale (NPRS) revealed that more than one-half (54.9%) of the individuals had ≥ 2 cerebral pain attacks for three months [29]. Majority of the individuals reported that their educational execution and ability to go to gatherings were affected during migraine attacks [30]. Headaches are one of the world's most ordinary conditions. Some, such as longing or stress headaches, vanish isolated and aren't a justification behind concern [31]. Headaches can be debilitating, but for specific people who experience symptoms with their headaches, they could be a marker for a more real danger - an extended risk for stroke [32]. For example, women who experience an air with their migraines have been exhibited to be at explicit risk [33]. Various climates may incorporate difficulty comprehension or conveying language, limb weakness on one side or harmony hardships [34].

MIGRAINES AND STROKE RISK

People who experience changes in their surrounding environments with their migraines have twofold the risk of stroke [35]. Studies have set up a basically higher risk of stroke among women who have migraines with air [36]. It is at this point it is difficult to say whether treating and hindering the migraines could achieve stroke danger decline however at this point affected women should stop smoking [37]. Since pregnancy increases the level of estrogen, women who have migraines with environment ought to be educated concerning their raised risk [38]. Additionally, a couple symptoms related with migraines may imitate the appearances of stroke [39]. Stroke is achieved by a blockage in the veins of the brain or by saturating the frontal cortex [40]. In all honesty, without suitable history and clinical appraisal and tests, it might be difficult to isolate among stroke and migraine in specific patient [41].

SEVERITY OF MIGRAINE

People who experience rehashing cerebral agonies of any sort should see a doctor for a cautious evaluation and appraisal because an exact finding is fundamental to convincing treatment [42]. Frequent episodes of cerebral pain and milder kinds of migraines may vanish with rest, loosening up, and over-the-counter solutions, or analgesics [43]. Prolonged migraine cerebral pain may require pain prescriptions [44]. A couple of cerebral pain are considered “alerts” since they could be achieved by an essential, life-risking condition [45]. Startling, phenomenal headache that tops to a horrendous control over seconds to minutes, much of the time portrayed as “the most observably awful cerebral aggravation of my life is life threatening [46]. In addition, cerebral pain that stirs you around during evening time or when resting should be taken seriously [47]. Besides cerebral pain joined by any signs, for instance, deficiency in the face, arm or leg; deadness or coordination issues; visual shortcoming; language or talk issues; tipsiness; confusion; changed readiness; or seizures requires urgent medical attention [48,49].

MIGRAINE TREATMENT

Cerebral pain is the most generally perceived kind of weakening fundamental headache and impacts around 12% of focused on Caucasian masses [50]. Non-pharmacological organization of cerebral pain by and large involves lifestyle appeal to help casualties with avoiding conditions in which attacks will be set off [51]. Preventive meds for migraine should ordinarily be viewed as founded on attack repeat such as ibuprofen or ergotamine, sumatriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan and frovatriptan – are extreme serotonin, 5-HT_{1B/1D}, receptor agonists which address a significant stage forward in the treatment of serious migraine [52,53].

CONCLUSION

Thus, migraine is a serious medical condition with level of severity varying from person to person with respect to age and gender along with prominent signs and symptoms.

REFERENCES

- Lipton RB, Bigal ME. The epidemiology of migraine. *Am J Med*. 2005 Mar;118 Suppl 1:3S-10S. doi: 10.1016/j.amjmed.2005.01.014. PMID: 15841882.
- Silberstein SD, Lipton RB. Epidemiology of migraine. *Neuroepidemiology*. 1993;12(3):179-94. doi: 10.1159/000110317. PMID: 8272178.
- Younger DS. Epidemiology of Migraine. *Neurol Clin*. 2016 Nov;34(4):849-861. doi: 10.1016/j.ncl.2016.06.011. PMID: 27719997.
- Sanvito WL, Monzillo PH, Peres MF, Martinelli MO, Fera MP, Gouveia DA, Murachovsky J, Salomão WR, Leme RJ. The epidemiology of migraine in medical students. *Headache*. 1996 May;36(5):316-9. doi: 10.1046/j.1526-4610.1996.3605316.x. PMID: 8682674.
- Wang SJ. Epidemiology of migraine and other types of headache in Asia. *Curr Neurol Neurosci Rep*. 2003 Mar;3(2):104-8. doi: 10.1007/s11910-003-0060-7. PMID: 12583837.
- Manzoni GC, Torelli P. Epidemiology of migraine. *The Journal of Headache and Pain*. 2003;4(1):s18-s22. <https://bit.ly/3tZwBMD>
- Merikangas KR. Contributions of epidemiology to our understanding of migraine. *Headache*. 2013 Feb;53(2):230-46. doi: 10.1111/head.12038. PMID: 23432441.
- Hedborg K, Anderberg UM, Muhr C. Stress in migraine: personality-dependent vulnerability, life events, and gender are of significance. *Ups J Med Sci*. 2011 Aug;116(3):187-99. doi: 10.3109/03009734.2011.573883. Epub 2011 Jun 14. PMID: 21668386; PMCID: PMC3128723.
- Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. *Cephalalgia*. 2010 May;30(5):599-609. doi: 10.1111/j.1468-2982.2009.01941.x. PMID: 19614702.
- Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. *Cephalalgia*. 1993 Jun;13(3):151-65. doi: 10.1046/j.1468-2982.1993.1303151.x. PMID: 8395342.
- Villalón CM, Centurión D, Valdivia LF, de Vries P, Saxena PR. Migraine: pathophysiology, pharmacology, treatment and future trends. *Curr Vasc Pharmacol*. 2003 Mar;1(1):71-84. doi: 10.2174/1570161033386826. PMID: 15320857.
- Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. *Drugs*. 2000 Dec;60(6):1259-87. doi: 10.2165/00003495-200060060-00003. PMID: 11152011.
- Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. *Eur J Neurol*. 2009 Sep;16(9):968-81. doi: 10.1111/j.1468-1331.2009.02748.x. PMID: 19708964.
- Villalón CM, Centurión D, Valdivia LF, De Vries P, Saxena PR. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. In *PROCEEDINGS-WESTERN PHARMACOLOGY SOCIETY*. 2002;45:199-210. [Western Pharmacology Society]. 1998.
- Arulmozhi DK, Veeranjanyulu A, Bodhankar SL. Migraine: current concepts and emerging therapies. *Vascul Pharmacol*. 2005 Sep;43(3):176-87. doi: 10.1016/j.vph.2005.07.001. PMID: 16099727.
- Amrutkar DV, Ploug KB, Hay-Schmidt A, Porreca F, Olesen J, Jansen-Olesen I. mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. *Pain*. 2012 Apr;153(4):830-838. doi: 10.1016/j.pain.2012.01.005. Epub 2012 Feb 4. PMID: 22305629.
- Goadsby PJ. Post-triptan era for the treatment of acute migraine. *Curr Pain Headache Rep*. 2004 Oct;8(5):393-8. doi: 10.1007/s11916-996-0013-3. PMID: 15361324.
- Neeb L, Meents J, Reuter U. 5-HT_{1F} Receptor agonists: a new treatment option for migraine attacks? *Neurotherapeutics*. 2010 Apr;7(2):176-82. doi: 10.1016/j.nurt.2010.03.003. PMID: 20430316; PMCID: PMC5084098.
- Hargreaves RJ, Shephard SL. Pathophysiology of migraine--new insights. *Can J Neurol Sci*. 1999 Nov;26 Suppl 3:S12-9. doi: 10.1017/s031716710000147. PMID: 10563228.
- Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. *Cephalalgia*. 1992 Aug;12(4):221-8; discussion 186. doi: 10.1046/j.1468-2982.1992.1204221.x. PMID: 1525797.
- Russell MB, Ulrich V, Gervil M, Olesen J. Migraine without aura and migraine with aura are distinct disorders. A population-based twin survey. *Headache*. 2002 May;42(5):332-6. doi: 10.1046/j.1526-4610.2002.02102.x. PMID: 12047331.
- Russell MB, Ulrich V, Gervil M, Olesen J. Migraine without aura and migraine with aura are distinct disorders. A population-based twin survey. *Headache*. 2002 May;42(5):332-6. doi: 10.1046/j.1526-4610.2002.02102.x. PMID: 12047331.
- Pietrobon D, Moskowitz MA. Pathophysiology of migraine. *Annu Rev Physiol*. 2013;75:365-91. doi: 10.1146/annurev-physiol-030212-183717. Epub 2012 Nov 26. PMID: 23190076.
- Allais G, Chiarle G, Sinigaglia S, Airola G, Schiapparelli P, Benedetto C. Gender-related differences in migraine. *Neurol Sci*. 2020 Dec;41(Suppl 2):429-436. doi: 10.1007/s10072-020-04643-8. PMID: 32845494; PMCID: PMC7704513.

25. Peterlin BL, Gupta S, Ward TN, Macgregor A. Sex matters: evaluating sex and gender in migraine and headache research. *Headache*. 2011 Jun;51(6):839-42. doi: 10.1111/j.1526-4610.2011.01900.x. PMID: 21631471; PMCID: PMC3975603.
26. Finocchi C, Strada L. Sex-related differences in migraine. *Neurol Sci*. 2014 May;35 Suppl 1:207-13. doi: 10.1007/s10072-014-1772-y. PMID: 24867868.
27. Bolay H, Ozge A, Saginc P, Orekici G, Uludüz D, Yalin O, Siva A, Bıçakçı Ş, Karakurum B, Öztürk M. Gender influences headache characteristics with increasing age in migraine patients. *Cephalalgia*. 2015 Aug;35(9):792-800. doi: 10.1177/0333102414559735. Epub 2014 Nov 25. PMID: 25424708.
28. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. *Cephalalgia*. 2003 Sep;23(7):519-27. doi: 10.1046/j.1468-2982.2003.00568.x. PMID: 12950377.
29. Ibrahim NK, Alotaibi AK, Alhazmi AM, Alshehri RZ, Saimaldaher RN, Murad MA. Prevalence, predictors and triggers of migraine headache among medical students and interns in King Abdulaziz University, Jeddah, Saudi Arabia. *Pak J Med Sci*. 2017 Mar-Apr;33(2):270-275. doi: 10.12669/pjms.332.12139. PMID: 28523020; PMCID: PMC5432687.
30. El-Metwally A, Toivola P, AlAhmary K, Bahkali S, AlKhatthami A, Al Ammar SA, Altamimi IM, Alosaimi SM, Jawed M, Almustanyir S. The Epidemiology of Migraine Headache in Arab Countries: A Systematic Review. *ScientificWorldJournal*. 2020 Jun 16;2020:4790254. doi: 10.1155/2020/4790254. PMID: 32607079; PMCID: PMC7315321.
31. Lipton RB, Goadsby PJ, Sawyer JP, Blakeborough P, Stewart WF. Migraine: diagnosis and assessment of disability. *Reviews in Contemporary Pharmacotherapy*. 2000;11(2):63-73.
32. El Hasnaoui A, Vray M, Richard A, Nachit-Ouinekh F, Boureau F; MIGSEV Group. Assessing the severity of migraine: development of the MIGSEV scale. *Headache*. 2003 Jun;43(6):628-35. doi: 10.1046/j.1526-4610.2003.03105.x. PMID: 12786922.
33. Lipton RB, Stewart WF, Von Korff M. The burden of migraine. *Pharmacoeconomics*. 1994;6(3):215-221.
34. Dowson AJ. Assessing the impact of migraine. *Curr Med Res Opin*. 2001;17(4):298-309. PMID: 11922404.
35. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. *Am J Med*. 2010 Jul;123(7):612-24. doi: 10.1016/j.amjmed.2009.12.021. Epub 2010 May 20. PMID: 20493462; PMCID: PMC2900472.
36. Rothrock J, North J, Madden K, Lyden P, Fleck P, Dittrich H. Migraine and migrainous stroke: risk factors and prognosis. *Neurology*. 1993 Dec;43(12):2473-6. doi: 10.1212/wnl.43.12.2473. PMID: 8255442.
37. Sacco S, Kurth T. Migraine and the risk for stroke and cardiovascular disease. *Curr Cardiol Rep*. 2014 Sep;16(9):524. doi: 10.1007/s11886-014-0524-1. PMID: 25059466.
38. Kurth T, Slomke MA, Kase CS, Cook NR, Lee IM, Gaziano JM, Diener HC, Buring JE. Migraine, headache, and the risk of stroke in women: a prospective study. *Neurology*. 2005 Mar 22;64(6):1020-6. doi: 10.1212/01.WNL.0000154528.21485.3A. PMID: 15781820.
39. Øie LR, Kurth T, Gulati S, Dodick DW. Migraine and risk of stroke. *J Neurool Neurosurg Psychiatry*. 2020 Jun;91(6):593-604. doi: 10.1136/jnnp-2018-318254. Epub 2020 Mar 26. PMID: 32217787; PMCID: PMC7279194.
40. Bousser MG, Welch KM. Relation between migraine and stroke. *Lancet Neurol*. 2005 Sep;4(9):533-42. doi: 10.1016/S1474-4422(05)70164-2. PMID: 16109360.
41. MacClellan LR, Giles W, Cole J, Wozniak M, Stern B, Mitchell BD, Kittner SJ. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. *Stroke*. 2007 Sep;38(9):2438-45. doi: 10.1161/STROKEAHA.107.488395. Epub 2007 Aug 9. PMID: 17690308.
42. Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. *Headache*. 2013 Mar;53(3):427-36. doi: 10.1111/head.12074. Epub 2013 Mar 7. PMID: 23470015.
43. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. *Headache*. 2001 Jul-Aug;41(7):638-45. doi: 10.1046/j.1526-4610.2001.041007638.x. PMID: 11554951.
44. Zeitlin C, Oddy M. Cognitive impairment in patients with severe migraine. *Br J Clin Psychol*. 1984 Feb;23 (Pt 1):27-35. doi: 10.1111/j.2044-8260.1984.tb00623.x. PMID: 6697026.
45. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. *Headache: The Journal of Head and Face Pain*. 2004;44(7):642-651.
46. Berg J, Stovner LJ. Cost of migraine and other headaches in Europe. *Eur J Neurol*. 2005 Jun;12 Suppl 1:59-62. doi: 10.1111/j.1468-1331.2005.01192.x. PMID: 15877781.
47. Holroyd KA, Drew JB, Cottrell CK, Romanek KM, Heh V. Impaired functioning and quality of life in severe migraine: the role of catastrophizing and associated symptoms. *Cephalalgia*. 2007 Oct;27(10):1156-65. doi: 10.1111/j.1468-2982.2007.01420.x. Epub 2007 Sep 4. PMID: 17784854; PMCID: PMC2128721.
48. Doenicke A, Brand J, Perrin VL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. *Lancet*. 1988 Jun 11;1(8598):1309-11. doi: 10.1016/s0140-6736(88)92122-8. PMID: 2897560.
49. Klapper JA, Stanton J. Current emergency treatment of severe migraine headaches. *Headache*. 1993 Nov-Dec;33(10):560-2. doi: 10.1111/j.1526-4610.1993.hed3310560.x. PMID: 8294195.
50. Welch KMA. Drug therapy of migraine. *New England Journal of Medicine*. 1993;329(20):1476-1483. doi: 10.1056/NEJM19931113292008
51. Silberstein SD. Preventive Migraine Treatment. *Continuum (Minneapolis)*. 2015 Aug;21(4 Headache):973-89. doi: 10.1212/CON.000000000000199. PMID: 26252585; PMCID: PMC4640499.
52. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. *Cephalalgia*. 2002 Oct;22(8):633-58. doi: 10.1046/j.1468-2982.2002.00404.x. Erratum in: *Cephalalgia*. 2003 Feb;23(1):71. PMID: 12383060.
53. Agosti RM. 5HT1F- and 5HT7-receptor agonists for the treatment of migraines. *CNS Neurol Disord Drug Targets*. 2007 Aug;6(4):235-7. doi: 10.2174/187152707781387242. PMID: 17691977.